India: Still a Land of Opportunity for MNCs
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India…
india
MNCs’ Healthcare Access Initiatives in India
With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to the country’s vast population, two pioneering pharmaceutical multinationals – Novartis and Janssen -…
Africa: The Launchpad for Indian Pharma
Although most industry observers expect that Indian pharma exports to the US will pick up again in the coming…
Indian Pharma Manufacturing: Serving the World
Indian pharma production is growing rapidly – boosted by the Modi government’s ‘Make in India’ campaign…
In Conversation
Bhupendra Sangani – CEO, Galentic, India
Bhupendra Sangani, founder and managing director of Galentic, one of India’s expert manufacturers of sterile and non-sterile semi-solid products in the dermatology and ophthalmology arenas, provides insights into the international development of his ambitious company in 40+ export markets. In line with the recent set up of Galentic’s new manufacturing plant in Gujarat and the expected US FDA approval of…
India Pharma Market Facts & Figures Snapshot
India’s pharmaceutical sales and forecast from 2013 up to 2021. Between 2017 and 2021, the Indian pharma…
Related Report
How Beneficial Is The Recent Price Control Exemption For Innovative Drugs In…
Anay Shukla leads the pharmaceutical, life sciences, med-tech and healthcare practice at Nishith Desai Associates,…
India: Creating An Innovative Healthcare Ecosystem
At the Organization of Pharmaceuticals Producers of India (OPPI), the association representing the research-based…
Meeting US FDA Standards Across the Board in India
In a context where even well-established, multi-billion-dollar domestic companies have received warning letters…
Colombia: The Great Indian Investment Wave
With the onset of universal public healthcare, new types of foreign actors have been spying fresh opportunities to…
India: Good Endings, Good Beginnings
What probably best explains the contrasts in the Indian pharmaceutical landscape is the fact that India can take…
Healthcare Politics in 2019
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In this article, he gives his predictions for…
Gender Diversity in Indian Pharma
India could boost its GDP by USD 0.7 trillion in 2025 by matching the rate of improvement of gender equality of the…
Indian Biosimilars: Going Global
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven…
India Healthcare: “Modicare” Lives On
Aditya Bhattacharji is Healthcare Practice Head at Eurasia Group. In this article, he looks at India’s…
Quality Compliance in Indian Pharma: The Learning Curve
One issue grinding the gears of the Indian pharmaceutical industry over recent years has been quality compliance.…
Indian Contract Research Industry Set for Rapid Growth
The global pharmaceutical outsourcing market was estimated to be USD 115.7 billion in 2016, of which 49 percent is…